Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial.

Tytuł:: Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial.
Autorzy:: Foy CG; Division of Public Health Sciences, Department of Social Sciences and Health Policy.
Lovato LC; Division of Public Health Sciences, Department of Biostatistical Sciences.
Vitolins MZ; Division of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Bates JT; Michael E. DeBakey VAMC and Baylor College of Medicine, Houston, Texas.
Campbell R; Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Cushman WC; Veterans Affairs Medical Center, Preventive Medicine Section, Medical Service, Memphis, Tennessee.
Glasser SP; Department of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Gillespie A; Division of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
Kostis WJ; Division of Cardiovascular Disease and Hypertension, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.
Krousel-Wood M; Departments of Medicine and Epidemiology, Ochsner Health System, Tulane University, New Orleans, Louisiana.
Muhlestein JB; Intermountain Medical Center Heart Institute, Murray.; University of Utah School of Medicine, Salt Lake City, Utah.
Oparil S; Division of Cardiovascular Disease, Department of Medicine, Vascular Biology and Hypertension Program, University of Alabama at Birmingham (UAB), Birmingham, Alabama.
Osei K; Division of Endocrinology, Diabetes and Metabolism, The Ohio State University Medical Center, Columbus, Ohio.
Pisoni R; Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Segal MS; Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainsville, Florida.
Wiggers A; Cleveland Medical Center, UH Harrington Heart and Vascular Institute, Cleveland, Ohio.
Johnson KC; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Corporate Authors:: SPRINT Study Research Group
Źródło:: Journal of hypertension [J Hypertens] 2018 Apr; Vol. 36 (4), pp. 904-915.
Typ publikacji:: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
Język:: English
Imprint Name(s):: Publication: [Alphen aan den Rijn, the Netherlands] : Wolters Kluwer Health, Inc.
Original Publication: London ; New York : Gower Academic Pub., [1983-
MeSH Terms:: Blood Pressure*
Antihypertensive Agents/*therapeutic use
Cardiovascular Diseases/*epidemiology
Acute Coronary Syndrome/epidemiology ; Aged ; Cardiovascular Diseases/mortality ; Female ; Heart Failure/epidemiology ; Humans ; Hypertension/drug therapy ; Hypertension/physiopathology ; Incidence ; Kidney Diseases/epidemiology ; Male ; Middle Aged ; Myocardial Infarction/epidemiology ; Patient Care Planning ; Proportional Hazards Models ; Sex Factors ; Stroke/epidemiology ; Systole ; United States/epidemiology
References:: Hypertension. 2016 Feb;67(2):263-5. (PMID: 26553234)
JAMA. 2014 Feb 5;311(5):507-20. (PMID: 24352797)
J Clin Lipidol. 2016 Jul-Aug;10(4):833-841. (PMID: 27578114)
Eur Heart J. 2008 Nov;29(21):2669-80. (PMID: 18852183)
Clin Sci (Lond). 2016 Apr;130(8):551-63. (PMID: 26957643)
Kidney Int Suppl (2011). 2013 Dec;3(4):352-356. (PMID: 25028640)
Hypertension. 2008 Apr;51(4):952-9. (PMID: 18259027)
J Am Coll Cardiol. 2012 Feb 7;59(6):572-82. (PMID: 22300691)
J Womens Health (Larchmt). 2012 Apr;21(4):379-87. (PMID: 22303820)
Am J Physiol Regul Integr Comp Physiol. 2004 Feb;286(2):R233-49. (PMID: 14707008)
J Clin Endocrinol Metab. 1999 Jun;84(6):1862-6. (PMID: 10372676)
Lancet. 2016 Mar 5;387(10022):957-967. (PMID: 26724178)
Hypertension. 2008 Apr;51(4):1142-8. (PMID: 18259031)
Hypertens Res. 2012 Feb;35(2):148-52. (PMID: 22129517)
Clin Trials. 2014 Oct;11(5):532-46. (PMID: 24902920)
Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):135-42. (PMID: 20160159)
Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. (PMID: 17599422)
Nutr Metab Cardiovasc Dis. 2014 Dec;24(12):1253-61. (PMID: 25149893)
Curr Cardiol Rep. 2016 Oct;18(10):98. (PMID: 27566331)
Lancet. 2005 Jan 15-21;365(9455):217-23. (PMID: 15652604)
JAMA. 1993 Aug 11;270(6):713-24. (PMID: 8336373)
Hypertension. 2008 Apr;51(4):1149-55. (PMID: 18259013)
Cardiol Rev. 2007 Nov-Dec;15(6):275-8. (PMID: 18090061)
Clin Trials. 2016 Jun;13(3):319-30. (PMID: 26911833)
J Gerontol A Biol Sci Med Sci. 2009 Feb;64(2):256-63. (PMID: 19181717)
Circulation. 2016 Jan 26;133(4):447-54. (PMID: 26811276)
Ann Intern Med. 1999 Mar 16;130(6):461-70. (PMID: 10075613)
JAMA. 2003 Oct 8;290(14):1884-90. (PMID: 14532317)
Am J Hypertens. 2008 Aug;21(8):910-6. (PMID: 18566594)
Ann Intern Med. 2017 Sep 19;167(6):375-383. (PMID: 28869987)
J Hypertens. 2011 May;29(5):1005-11. (PMID: 21330934)
JAMA. 2003 May 21;289(19):2560-72. (PMID: 12748199)
J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019)
Womens Health (Lond). 2011 May;7(3):341-52; quiz 352-3. (PMID: 21612354)
Am J Med. 2016 Oct;129(10):1030-6. (PMID: 27427323)
J Am Geriatr Soc. 2007 Jul;55(7):1056-65. (PMID: 17608879)
J Gen Intern Med. 2014 Dec;29(12):1599-606. (PMID: 25127725)
Clin Interv Aging. 2009;4:379-89. (PMID: 19851513)
Curr Cardiovasc Risk Rep. 2016 Jan;10:. (PMID: 28149430)
Circulation. 2013 Jan 1;127(1):143-52. (PMID: 23283859)
J Am Coll Cardiol. 2016 Feb 9;67(5):463-72. (PMID: 26562046)
J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941)
J Womens Health (Larchmt). 2006 Jan-Feb;15(1):54-6. (PMID: 16417419)
Hypertension. 2008 Nov;52(5):818-27. (PMID: 18852389)
Circulation. 2017 Mar 7;135(10):e146-e603. (PMID: 28122885)
Med Sci Sports Exerc. 2004 Mar;36(3):533-53. (PMID: 15076798)
Curr Hypertens Rep. 2013 Aug;15(4):321-30. (PMID: 23749317)
N Engl J Med. 2015 Nov 26;373(22):2103-16. (PMID: 26551272)
Grant Information:: UL1 TR000433 United States TR NCATS NIH HHS; UL1 TR000445 United States TR NCATS NIH HHS; UL1 TR000064 United States TR NCATS NIH HHS; UL1 TR000075 United States TR NCATS NIH HHS; P30 DK079626 United States DK NIDDK NIH HHS; UL1 TR000093 United States TR NCATS NIH HHS; U54 GM104940 United States GM NIGMS NIH HHS; UL1 TR000003 United States TR NCATS NIH HHS; UL1 TR000050 United States TR NCATS NIH HHS; UL1 RR025755 United States RR NCRR NIH HHS; UL1 RR024134 United States RR NCRR NIH HHS; HHSN268200900048C United States HL NHLBI NIH HHS; UL1 TR000005 United States TR NCATS NIH HHS; HHSN268200900040C United States HL NHLBI NIH HHS; HHSN268200900046C United States HL NHLBI NIH HHS; P30 GM103337 United States GM NIGMS NIH HHS; UL1 TR001064 United States TR NCATS NIH HHS; UL1 RR025752 United States RR NCRR NIH HHS; UL1 RR025771 United States RR NCRR NIH HHS; HHSN268200900049C United States HL NHLBI NIH HHS; HHSN268200900047C United States HL NHLBI NIH HHS; UL1 TR000439 United States TR NCATS NIH HHS; UL1 TR000073 United States TR NCATS NIH HHS; UL1 TR000002 United States TR NCATS NIH HHS; UL1 TR000105 United States TR NCATS NIH HHS
Molecular Sequence:: ClinicalTrials.gov NCT01206062
Substance Nomenclature:: 0 (Antihypertensive Agents)
Entry Date(s):: Date Created: 20180302 Date Completed: 20190614 Latest Revision: 20231113
Update Code:: 20240104
PubMed Central ID:: PMC7199892
DOI:: 10.1097/HJH.0000000000001619
PMID:: 29493562
: Czasopismo naukowe

Background: To determine if the effects of intensive lowering of systolic blood pressure (goal of less than 120 mmHg) versus standard lowering (goal of less than 140 mmHg) upon cardiovascular, renal, and safety outcomes differed by gender.
Methods: Nine thousand three hundred and sixty-one men and women aged 50 years or older with systolic blood pressure of 130 mmHg or greater, taking 0-4 antihypertensive medications, and with increased risk of cardiovascular disease, but free of diabetes, were randomly assigned to either a systolic blood pressure target of less than 120 mmHg (intensive treatment) or a target of less than 140 mmHg (standard treatment). The primary composite outcome encompassed incident myocardial infarction, heart failure, other acute coronary syndromes, stroke, or cardiovascular-related death. All-cause mortality, renal outcomes, and serious adverse events were also assessed.
Results: Compared with the standard treatment group, the primary composite outcome in the intensive treatment group was reduced by 16% [hazard ratio 0.84 (0.61-1.13)] in women, and by 27% in men [hazard ratio 0.73 (0.59-0.89), P value for interaction between treatment and gender is 0.45]. Similarly, the effect of the intensive treatment on individual components of the primary composite outcome, renal outcomes, and overall serious adverse events was not significantly different according to gender.
Conclusion: In adults with hypertension but not with diabetes, treatment to a systolic blood pressure goal of less than 120 mmHg, compared with a goal of less than 140 mmHg, resulted in no heterogeneity of effect between men and women on cardiovascular or renal outcomes, or on rates of serious adverse events.ClinicalTrials.gov number, NCT01206062.

Comment in: J Hypertens. 2018 Apr;36(4):768-770. (PMID: 29489615)

Informacja